In comparison, the randomized Keynote 522 trial evaluating the addition of pembrolizumab to neoadjuvant chemotherapy for TNBC [26] and the KRISTINE trial [27], randomly assigning participants to trastuzumab emtansine plus pertuzumab or docetaxel, carboplatin, and trastuzumab plus pertuzumab, were designed to detect a pCR difference of 15%, but based on the already high pCR rates seen in TNBC and HER2-positive BC. This evidence concerns the gene ERBB2 and breast cancer.